Actively Recruiting
Glaukos® iStent Infinite Trabecular Micro-Bypass System in Subjects With Mild to Moderate Primary Open-angle Glaucoma
Led by Glaukos Corporation · Updated on 2023-09-28
245
Participants Needed
1
Research Sites
204 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Prospective, multicenter, single-arm study of the iStent infinite in adult pseudophakic or phakic subjects with mild to moderate primary open angle glaucoma who have not failed conventional medical and surgical treatment
CONDITIONS
Official Title
Glaukos® iStent Infinite Trabecular Micro-Bypass System in Subjects With Mild to Moderate Primary Open-angle Glaucoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of primary open-angle glaucoma
- Phakic or pseudophakic status
- Age 35 years or older
You will not qualify if you...
- Traumatic, uveitic, neovascular, or angle-closure glaucoma
- Glaucoma associated with vascular disorders
- Active corneal inflammation or edema
- Retinal disorders not associated with glaucoma
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Glaukos Investigator Site
Cincinnati, Ohio, United States, 45242
Actively Recruiting
Research Team
D
Dari Parizadeh
CONTACT
K
Kerry Stephens
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here